.


:

:



,



( , )

:

































 

 

 

 
FAQ

.

⇐ 12



. , .

(- , , , ).

( -- ) , . , , , EBV CMV 4-7 .

, , , , .

- , .

/ , , .

, , , . PlummerVinson 40 70 . , , - , . Eagle () , , , . ( ) , .

3 , .

3.

 

 

, - ( ) ( ) , - , , , Neisseria gonorrhoeae , 2 ( , ) , ( )

 

. ( , ), ( , ).

:

- ( , );

- ( ( , , , ) ( );

- (, , , );

- .

() ( , , - --). . , . , 20-30% 5-15% . , 95% , .. 65% - . , 71% .

:

- ();

- ( );

- ( );

- .

 

.

( , , ) .

100% - in vitro , , - .

( ) ( I). ( I). , ( .. ) - (.. ). , ( ) .

100% in vitro , .

: - , -; - ; ; .

( , ) 48-72 . ( , ), .

- II-III , .. 1,9% 0,6% II III ( II).

- II-III ( II), , . , 14- (, , ) 15- () , 16- (. , ) - .

, , 10 (5 ) ( I). (5-7 ) II-III , .

( ), ) - ( II).

, 4.

 

4. .

1,5 / 3 m<25 0,375 / 2 , m>25 750 / 3 1 10
* 1,5 / 3 2,0 2 50 // 2-3 10
-** 2,4 / m<27 600 ., m>27 1,2 /
1,0 2 40 // 2 30-60 10
1,0 / 2 20 // 2 10
400 / 1 9 // 1 10
400 / 1 8 // 1 10
  ***,**** 1,5 / 3 40 // 3 1 10
**** 500 / 1 12 // 1 1 5
**** 500 / 2 15 // 2 10
1,0 / 2 40 // 2 10
1,2 / 3 50 // 2 1 10
6 / 2 m>20 300 // 2 10
-
***** 0,6 / 4 20 // 3 10
***** 1,5 / 3 30 // 3 1 10

*

** : ) () ; ) ; ) - ; ) - , , , , ..

*** , -

**** , 14- 15- , 16- (, , )

***** ; MLS- .

 

, , / 875/125 2 10 II-III ( , ), 16- ( II () III ())

( I).

, , , 50-100 / (: 3-6 //) 1 7-14 .

/ () . ( I) 10-15 8-10 // . ( 3 , , >39,5). .

 

, , , .

, .

:

-

-

, .. .

: , , , , , , , , , . () ( , ).

. in vitro , , , , , (Candida albicans) Mycoplasma pneumoniae. .

. , . .

, , , .

 

( , ):

- /

- (, 6 )

- /

-

-

 

:

- ( 2-3 )

- ( 8-10 )

- ( 8-10 )

-

- PANDAS ( , )

 

, , , , , , (-, , , - ) . , , , / .

 

 

, , .

, , , . (, ) .

( .. -), , - , , .

 

1. .. / .., .. : , 2005 4. .412-445.

2. .. - // Consillium medicum. 2000 2 - 2 .164-168

3. .., .. // ,2013.4-2014,1..20-25

4. . .., .. - .// . .

5. .. // ... 2010 129.

6. . .., ..,.2.-.: "",2005.-375-318

7. .., .., .. . Str.pyogenes : -1// .2005;7(2);154-166,4.

8. .. . /.. // , 9 16-17, 2001 .58-61

9. .., .., .., .., .., .., .., .., .. //

10. .. // . . 1991 - 4 .8-10

11. .. . Consilium medicum 2002; 4(1): 49.

12. .. , // , 1963 3, 9 .228-255

13. .. - . .: -, 2008 256.

14. / .., .. , .. . : , 2006, - 120 .

15. .. / .. // i - 6 (50) XI/XII 2005 - .65-69.

16. Adam D, Scholz H, Helmerking M. Treatment of group A streptococcal tonsillopharyngitis. 5 days cephalosporin is as effective as 10 days penicillin. MMW Fortschr Med. 2001 May 3;143(18):40

17. Antibiotics for sore throat. / C.B.Del Mar, P.P.Glasziou, A.B.Spinks / The Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD 000023. pub2.

18. ugrysheva J, Froehlich, BJ, Freiberg JA, Scott JR. Serine/threonine protein kinase Stk is required for virulence, stress response, and penicillin tolerance in Streptococcus pyogenes// Infect Immun, 2011 Oct; 79(10): 4201-9

19. Bergman A, Werner R Failure of children to receive penicillin by mouth. N Engl J Med. 1963 Jun 13;268:1334-8

20. Bisno AL et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America.// Clin Infect Dis. 2002; 35: 113-125

21. Bisno AL. Acute pharyngitis: etiology and diagnosis. Pediatrics 1996;97:94954

22. Bista M., Amatya RC., Basnet P. Tonsillar microbial flora: a comparison of infected and non-infected tonsils // Kathmandu Univ Med J 2006; 4(1): 18-21

23. Bloomington M.N. Acute pharyngitis. / M.N. Bloomington // Institute for Clinical Systems Improvement (SCSI), Institute for Clinical Systems Improvement (2005) - 33 - 50p.

24. Boccazzi A, Garotta M, Pontari S, Agostoni CV. Streptococcal tonsillopharyngitis: clinical vs. microbiological diagnosis// Infez Med. 2011 Jun;19(2):100-5.

25. Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012 May;42(5):612-20

26. Canton R., Loza E., Morosini M., Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J. Antimicrob. Chemother., 2002, 50 (Suppl. S1), 9-24.

27. Chiappini E, Regoli M, Bonsignori F, Sollai S, Parretti A, Galli L, de Martino M. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children // Clin Ther. 2011 Jan;33(1):48-58

28. Cowan D.L. Acate and chronic infection of the pharynx and tonsils / D.L.Cowan, J.Hibbert / Scott-Browns Otolaryngology, Sixth edition Oxford, 1997 vol.5 chapter 4 p.1-24.

29. Dagnelie C.F. Sore Throat in General Practice. A Diagnostic and Therapeutic Study. / C.F. Dagnelie // Thesis. Rotterdam, 1994.

30. Denny FW, Wannamaker LW, Brink WR, Rammelkamp CH Jr, Custer EA. Prevention of rheumatic fever; treatment of the preceding streptococcic infection.// J Am Med Assoc. 1950 May 13;143(2):151-3.

31. d'Humières C, Cohen R, Levy C, Bidet P, Thollot F, Wollner A, Bingen E. Decline in macrolide-resistant Streptococcus pyogenes isolates from French children // Int J Med Microbiol. 2012 Dec;302(7-8):300-3.

32. Ebell MH, Smith MA, Barry HC, Ives K, Carey M. The rational clinical examination. Does this patient have strep throat? JAMA 2000; 284:29128

33. Esposito S, Bosis S, Begliatti E, Droghetti R, et al. Acute tonsillopharyngitis associated with atypical bacterial infection in children: natural history and impact of macrolide therapy // Clin Infect Dis 2006; 43(2): 206-9.

34. Feder HM Jr, Gerber MA, Randolph MF, Stelmach PS, Kaplan EL.

35. Gwaltney J.M. Pharyngitis. / J.M. Gwaltney // In: Mandell G.L., Bennet J.E., Dolin R., editors, Principles and Practice of Infectious Diseases. 4th Edition. NY: Churchill Livingstone 1996, 5669.

36. Hansaker D.H. Etiology of Infectious Diseases of the Upper Respiratory Tract. / D.H.Hansaker, J.L.Boone // In: Ballenger J.J., Snow J.B., editors, Otorhinolaryngology: Head and Neck Surgery. 15th edition. Baltimore: Williams & Wilkins, 1996, 6983.

37. Jetlund O, Thurmann-Nielsen E, Walstad RA. Comparison of the serum and tissue concentrations of cefuroxime from cefuroxim axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy// Int J Clin Pharmacol Res. 1991; 11(1):1-6

38. Lafontaine ER, Wall D, Vanlerberg SL, Donabedian H, Sledjeski DD. Moraxella catarhalis coaggregates with Streptococcus pyogenes and modulates interactions of S.pyogenes with human epithelial cells.// Infect Immun. 2004 Nov; 72(11):6689-93

39. Management of sore throat and indications for tonsillectomy. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN), SIGN Publication 1999, Number 34, p.23

40. McIsaac WJ, Goel V, To T, Low DE. The validity of sore throat score in family practice // CMAJ 2000; 163(7): 811-815.

41. OSullivan L et al. Group A Streptococcal Sore Throat Management. //Evidence-based, best practice New Zealand Guidelines for Rheumatic Fever; 2008; 64 p.

42. Once-daily therapy for streptococcal pharyngitis with amoxicillin.Pediatrics 1999; 103:4751

43. Pelucchi C, Grigoryan L, Galeone C, Esposito S, Huovinen P, Little P, Verheij T. ESCMID Guideline for the Management of Acute Sore Throat.// Clin Microbiol Infect 2012; 18 (Suppl. 1): 127

44. Pichichero ME, Casey JR. Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis // Otolaryngol Head Neck Surg. 2007 Dec;137(6):851-857

45. ichichero M.E. The rising incidence of penicillin treatment failures in group A streptococcal tonsillopharyngitis: an emerging role for the cephalosporins?// Ped Inf Dis J, 1991;10: 50-5

46. Principles of appropriate antibiotic use for acute pharyngitis in adults: back-ground. / Cooper R.J., Hoffman J.R., Bartlett J.G. at al.// American Academy of Family Physicians; American College of Physicians American Society of Internal Medicine; Centers for Disease Control (2001) Ann. Intern. Med., 134(6): 509517.

47. Ressel G. Principles of appropriate antibiotic use: Acute pharyngitis. Part IV. Am. Fam. Physician / G. Ressel // Centers for Disease Control and Prevention, American College of Physicians-American Society of Internal Medicine, American Academy of Family Physicians, Infectious Diseases Society of America (2001) 64(5): 870-875.

48. Roos K, Holm SE, Grahn E, Lind L. Alpha-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study.// Scand J Inf Dis. 1993; 25(1):31-5

49. Scholz H. Streptococcal-A tonsillopharyngitis: a 5-day course of cefuroxime axetil versus a 10-day course of penicillin V. Results depending on childrens age. Chemotherapy -2004; 50(1):51-4

50. Snow V., Mottur-Pilson C., Cooper R.J., Hoffman J.R.; Principles of appropriate antibiotic use for acute pharyngitis in adults. Ann. Intern. Med., 2001, 134(6): 506-508.

51. Stanford T. Shulman, Alan L. Bisno, Herbert W. Clegg, Michael A. Gerber, Edward L. Kaplan, Grace Lee, Judith M. Martin, and Chris Van Beneden Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America//Clinical Infectious Diseases Advance Access published September 9, 2012

52. Sundberg L, Eden T, Ernstson S. The penetration of erythromycin into Waldeyers ring tonsoll and adenoid tissue// Infection. 1982; 10 (Suppl 2): S102-4

53. Van Driel ML, De Sutter AIM, Keber N, Habraken H, Christiaens T. Different antibiotic treatments for group A streptococcal pharyngitis (Review). Evid.-Based Child Health: A Cochrane review J. 2011; 7:1: 1681

54. van Duijn H., Kuyvenhoven M., Welschen I., den Ouden H., Slootweg A., Verheij T. Patients' and doctors' views on respiratory tract symptoms. Scand. J. Prim. Health Care 2002, 20(4): 201-202.

 

 

⇐ 12


:

: 2016-11-20; !; : 709 |

:

:

, .
==> ...

1727 - | 1546 -


© 2015-2024 lektsii.org - -

: 0.07 .